Quest Diagnostics Clinical Laboratories INC
Quest Diagnostics Clinical Laboratories INC was paid $48K by Medicaid between Jan 2018 and Jun 2023, across 19 billing codes. Its largest line is 88175, Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer — 19% of everything it billed.
HORSHAM, PA 19044
Next to other Clinical Medical Laboratory providers in Pennsylvania
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 320 | $1K | |
| 2021 | 146 | $2K | |
| 2022 | 631 | $11K | |
| 2023 | 1,342 | $34K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 19% | 325 | 318 | $9K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 18% | 258 | 258 | $9K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 12% | 87 | 85 | $6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 9.2% | 67 | 65 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 7.1% | 157 | 157 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 7.1% | 157 | 157 | $3K |
| 80053 | Comprehensive metabolic panel | 6.7% | 297 | 292 | $3K |
| 80061 | Lipid panel | 5.8% | 271 | 271 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.8% | 284 | 278 | $1K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 182 | 181 | $1K |
| 80074 | 1.9% | 20 | 20 | $933.60 | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.9% | 49 | 49 | $900.85 |
7 more codes
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.8% | 31 | $892.77 |
| 88112 | 1.4% | 65 | $670.71 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.3% | 26 | $649.42 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 20 | $472.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 98 | $450.17 |
| 36415 | Collection of venous blood by venipuncture | <1% | 30 | $88.20 |
| 86592 | <1% | 15 | $35.20 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.